Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Significance: Advanced prostate cancer is a deadly disease made up of multiple cancer subtypes that evolve during its natural history. Unfortunately, antibody- and cell-based therapies in development that target single tumor antigens found in conventional prostate cancer do not account for this heterogeneity. Here, we show that two major subtypes of advanced prostate cancer, prostate adenocarcinoma (PrAd) and neuroendocrine prostate cancer (NEPC), exhibit distinct cell-surface expression profiles. Integrated analysis of gene expression and cell-surface protein expression of prostate cancer nominated multiple subtype-specific cell-surface antigens. We specifically characterize FXYD3 and CEACAM5 as targets for immune-based therapies in PrAd and NEPC and provide preliminary evidence of the antigen-specific cytotoxic activity of CEACAM5-directed chimeric antigen receptor T cells in NEPC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063 · cited 1×
“The lineagespecific immunophenotyping of hematologic malignancies with CD molecules subsequently prompted the development of immunebased, targeted cancer therapies, including anti-CD20 antibodies (17) and recently CD19-directed CAR T (18, 19), which are transforming the treatment of B-cell malignancies.”
BackgroundSelf-citationOrganoid Cultures Derived from Patients with Advanced Prostate Cancer
Gao, D., Vela, I., Sboner, A., Iaquinta, P. J., Karthaus, W. R., Gopalan, A., Dowling, C., Wanjala, J. N., Undvall, E. A., Arora, V. K., et al. (2014) · Cell · doi:10.1016/j.cell.2014.08.016 · Cited by 1,559
Self-citationToil enables reproducible, open source, big biomedical data analyses
Vivian, J., Rao, A. A., Nothaft, F. A., Ketchum, C., Armstrong, J., Novak, A., Pfeil, J., Narkizian, J., Deran, A. D., Musselman-Brown, A., et al. (2017) · Nature Biotechnology · doi:10.1038/nbt.3772 · Cited by 1,365
Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling
Bluemn, E. G., Coleman, I. M., Lucas, J. M., Coleman, R. T., Hernandez-Lopez, S., Tharakan, R., Bianchi-Frias, D., Dumpit, R. F., Kaipainen, A., Corella, A. N., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.09.003 · Cited by 744 · cited 1×
“Recent work also indicates that a subset of CRPC assumes a doublenegative (AR- and neuroendocrine-negative) phenotype that is maintained by enhanced FGF and MAPK pathway signaling (2).”
BackgroundSelf-citationPlaisier, S. B., Taschereau, R., Wong, J. A., & Graeber, T. G. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq636 · Cited by 468 · cited 2×
“RRHO analysis was performed in pairwise comparisons of gene-expression datasets as described (25).”
MethodSelf-citation
Cited by
Labrecque, M. P., Coleman, I. M., Brown, L. G., True, L. D., Kollath, L., Lakely, B., Nguyen, H. M., Yang, Y. C., da Costa, R. M. G., Kaipainen, A., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci128212 · Cited by 464
Self-citationClinical and Biological Features of Neuroendocrine Prostate Cancer
Yamada, Y., & Beltran, H. (2021) · Current Oncology Reports · doi:10.1007/s11912-020-01003-9 · Cited by 305
Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer
Bakht, M. K., & Beltran, H. (2025) · Nature Reviews Urology · doi:10.1038/s41585-024-00900-z · Cited by 158
“Alternative radioligands can be designed by drawing from studies on systemic surfaceome profiling that identify target antigens 28,102 or adapted from radioligands that are currently in clinical use.”
The Cellular Immunotherapy Revolution: Arming the Immune System for Precision Therapy
Paucek, R. D., Baltimore, D., & Li, G. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.02.002 · Cited by 104
Zanvit, P., van Dyk, D., Fazenbaker, C., McGlinchey, K., Luo, W., Pezold, J. M., Meekin, J., Chang, C.-Y., Carrasco, R. A., Breen, S., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci169655 · Cited by 60
“Large-scale genomic and proteomic efforts have identified six-transmembrane epithelial antigen of prostate-2 (STEAP2; also known as STAMP1) as a superior prostate antigen for therapeutic targeting (5, 6).”
Background
Metadata
- Authors
- Lee, J. K., Bangayan, N. J., Chai, T., Smith, B. A., Pariva, T. E., Yun, S., Vashisht, A., Zhang, Q., Park, J. W., Corey, E., Huang, J., Graeber, T. G., Wohlschlegel, J., & Witte, O. N.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2018-04-23
- Volume
- 115
- Issue
- 19
- Pages
- E4473-E4482
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2801671624
- Cited by
- 147
- References
- 6
- FWCI
- 9.47
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer. https://app.cochat.ai/papers/10.1073/pnas.1802354115
- The paper
- Lee, J. K., Bangayan, N. J., Chai, T., Smith, B. A., Pariva, T. E., Yun, S., Vashisht, A., Zhang, Q., Park, J. W., Corey, E., Huang, J., Graeber, T. G., Wohlschlegel, J., & Witte, O. N. (2018). Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1802354115
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.